Find Funding Opportunities

The primary purpose of the Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented NIH-supported independent investigators. The program is designed to facilitate a timely transition from a mentored postdoctoral research position to a stable independent research position with independent NIH or other independent research support at an earlier stage than is currently the norm. Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS) invite research grant applications focused on elucidating the mechanisms of HIV-associated neuropathogenesis in the context of aging, chronic infection with HIV, and long term exposure to Highly Active Antiretroviral Therapy (HAART). The neuropathogenic mechanisms of HIV-Associated Neurocognitive Disorders (HAND) may be distinct in the aging HIV-infected populations given the potential interactions between aging associated events, HIV-associated neurodegenerative processes, and exposure to HAART. Understanding the pathogenesis of HAND in HIV-infected individuals over 50 years of age, in light of potential interactions with HAART, neurodegenerative diseases, and aging-related co-morbid conditions are the focus of this announcement. Applications ranging from basic research to clinical diagnosis and treatment in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged, but not required.

The National Institute of Mental Health (NIMH), the National Institute on Aging (NIA), and the National Institute of Neurological Disorders and Stroke (NINDS) invite research grant applications focused on elucidating the mechanisms of HIV-associated neuropathogenesis in the context of aging, chronic infection with HIV, and long term exposure to Highly Active Antiretroviral Therapy (HAART). The neuropathogenic mechanisms of HIV-Associated Neurocognitive Disorders (HAND) may be distinct in the aging HIV-infected populations given the potential interactions between aging associated events, HIV-associated neurodegenerative processes, and exposure to HAART. Understanding the pathogenesis of HAND in HIV-infected individuals over 50 years of age, in light of potential interactions with HAART, neurodegenerative diseases, and aging-related co-morbid conditions are the focus of this announcement. Applications ranging from basic research to clinical diagnosis and treatment in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged, but not required.

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to provide an opportunity for the NINDS American Recovery and Reinvestment Act (ARRA)-funded consortia to compete for another three years of participation in the Rare Diseases Clinical Research Network (RDCRN). The RDCRN is a collaborative and coordinated network of Clinical Research Consortia comprised of investigators and patient support groups committed to investigation of rare diseases working in partnership with the Data Management Coordinating Center to enhance communication and sharing of resources in a multidisciplinary approach. The RDCRN is focused on 1) the collection of clinical information to better define disease natural history and to develop biomarkers as well as new approaches to diagnosis, prevention, and treatment of rare diseases, and 2) training of new clinical investigators in rare diseases research.

The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible institutions as the primary means of supporting predoctoral and postdoctoral research training to help ensure that a diverse and highly trained workforce is available to assume leadership roles related to the Nations biomedical, behavioral and clinical research agenda. The objective of the T32 program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program supports predoctoral and postdoctoral research training programs (including those with short term research training) at domestic institutions of higher education with the T32 funding mechanism. Note that programs solely for short-term research training should not apply to this announcement, but rather the separate (T35) NRSA Short-Term Institutional program exclusively reserved for predoctoral and/or postdoctoral level short-term research training programs (see PA-11-185).

The purpose of this funding opportunity announcement (FOA) is to support investigator-initiated Research Project Grant (R01) applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social, and behavioral research supported by the participating NIH Institutes/Centers. The Office of Behavioral and Social Sciences Research (OBSSR) joins this FOA as part of its efforts to promote research on the behavioral and social aspects of health and illness. However, only participating ICs will provide direct grant support under this FOA.

The purpose of this funding opportunity announcement (FOA) is to support investigator-initiated Exploratory/Developmental Research Grant Award (R21) applications that propose to study high priority bioethical challenges and issues associated with the types of biomedical, social, and behavioral research supported by the participating NIH Institutes/Centers. The Office of Behavioral and Social Sciences Research (OBSSR) joins this FOA as part of its efforts to promote research on the behavioral and social aspects of health and illness. However, only participating ICs will provide direct grant support under this FOA.

This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant mechanism is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.

The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications for investigator-initiated, multi-site, randomized, controlled Phase III clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS).The trials may address any research question related to the mission and goals of the NINDS.Information about the mission, strategic plan and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/).

The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma drug development network to develop neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug development services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug development services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply.